Rheumatoid arthritis (RA) is an autoimmune disease, which is a worldwide disease, with a global prevalence rate of about 0.24%. RA pathogenesis is complex and has a high disability rate, depressing the life quality of patients seriously and aggravating the economic burden of the society. Effective treatment of RA has become a focus of the global pharmaceutical industry. According to the IMS Health statistics, the global drug expenditure for the treatment of RA amounted to $21.4 billion in 2015. This paper uses literature investigation, database search, such as Thomson Reuters, IMS Health etc., as well as data statistics and analysis, to make an analysis on the global RA drug development status, market, targets, patent and other information. Medicine treatment for RA includes anti-inflammatory drugs, anti-rheumatic drugs, hormone drugs, biological agents, combination of drugs, immune reconstitution, etc. Therapeutic target involves tumor necrosis factor alpha, cycloxygenase, B-lymphocyte antigen, interleukin, nuclear transcription factor kB, small molecule kinase and so on. In recent years, the development of biotechnology drugs in the treatment of RA and other autoimmune diseases has made an unprecedented success, small molecule drugs and biosimilar products will also play an important role in the future market.
LIU Lili
,
MAO Yanyan
,
GAO Liubin
. An analysis on global drug development status of rheumatoid arthritis[J]. Science & Technology Review, 2016
, 34(24)
: 44
-55
.
DOI: 10.3981/j.issn.1000-7857.2016.24.006
[1] Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis:smoking may trigger HLA-DR (shared epitope)-re-stricted immune reactions to autoantigens modified by citrullination[J]. Arthritis & Rheumatism, 2006, 54(1):38-46.
[2] Hitchon C A, El-Gabalawy H S. The synovium in rheumatoid arthritis[J]. The Open Rheumatology Journal, 2011, 5:107-114.
[3] McInnes I B, Schett G. Cytokines in the pathogenesis of rheumatoid ar-thritis[J]. Nature Reviews Immunology, 2007, 7(6):429-442.
[4] McInnes I B, Buckley C D, Isaacs J D. Cytokines in rheumatoid arthri-tis[mdash] shaping the immunological landscape[J]. Nature Reviews Rheumatology, 2015, 12:63-68.
[5] Cross M, Smith E, Carmona L, et al. The global burden of rheumatoid arthritis:Estimates from the global burden of disease 2010 study[J]. An-nals of the Rheumatic Diseases, 2014, 73(7):1316-1322.
[6] Vos T, Barber R M, Bell B, et al. Global, regional, and national inci-dence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013:A systemat-ic analysis for the Global Burden of Disease Study 2013[J]. The Lancet, 2015, 386(9995):743-800.
[7] Helmick C G, Felson D T, Lawrence R C, et al. Estimates of the preva-lence of arthritis and other rheumatic conditions in the United States:Part I[J]. Arthritis & Rheumatism, 2008, 58(1):15-25.
[8] Wilddifield J, Paterson J M, Bernatsky S, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada[J]. Arthritis & Rheumatism, 2014, 66(4):786-793.
[9] Yamanaka H, Sugiyama N, Inoue E, et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan us-ing reimbursement data from health insurance societies and the IORRA cohort (I)[J]. Modern Rheumatology, 2014, 24(1):33-40.
[10] Mok C C, Tam L S, Chan T H, et al. Management of rheumatoid arthri-tis:consensus recommendations from the Hong Kong Society of Rheu-matology[J]. Clinical rheumatology, 2011, 30(3):303-312.
[11] Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis[J]. Best Practice & Research Clinical Rheumatology, 24(6):733-745.
